Janssen’s Nipocalimab Among Six New EU Filings

 
• By Neena Brizmohun

Nipocalimab is an investigational FcRn blocker for treating generalized myasthenia gravis that was also recently filed for regulatory review in the US.

The EMA is reviewing new drugs for potential marketing approval • Source: Shutterstock

More from Europe

More from Geography